ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by Bank of Montreal Can (2025)

Bank of Montreal Can cut its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA – Free Report) by 98.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 26,562 shares of the biotechnology company’s stock after selling 2,059,760 shares during the quarter. Bank of Montreal Can’s holdings in ADMA Biologics were worth $456,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Perpetual Ltd acquired a new position in ADMA Biologics during the fourth quarter worth $62,300,000. Lord Abbett & CO. LLC purchased a new stake in shares of ADMA Biologics in the third quarter valued at about $61,858,000. Allspring Global Investments Holdings LLC increased its position in ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock worth $51,016,000 after purchasing an additional 2,613,482 shares during the last quarter. Raymond James Financial Inc. purchased a new position in ADMA Biologics during the fourth quarter worth about $19,076,000. Finally, Principal Financial Group Inc. boosted its holdings in ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after purchasing an additional 1,059,394 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $19.64 on Tuesday. The company has a market cap of $4.64 billion, a P/E ratio of 70.14 and a beta of 0.53. ADMA Biologics, Inc. has a 1-year low of $6.19 and a 1-year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The stock has a 50-day moving average of $18.33 and a two-hundred day moving average of $18.21.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.

Check Out Our Latest Stock Report on ADMA Biologics

ADMA Biologics Company Profile

(Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Featured Stories

• Five stocks we like better than ADMA Biologics
• Why Are Stock Sectors Important to Successful Investing?
• AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock
• Best Stocks Under $10.00
• Why Call Option Traders Are Targeting This Dividend ETF Now
• Best Stocks Under $5.00
• Is Alphabet Misunderstood? Here’s Why the Bulls Are Buying

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. (NASDAQ:ADMA – Free Report).

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.